Korean J Hematol.  2007 Dec;42(4):317-324. 10.5045/kjh.2007.42.4.317.

Outcome of Hematopoietic Stem Cell Transplantation: In Children and Adolescent Patients at Yeungnam University Hospital

• Lee YJ
• Lee HD
• Hah JO
• Kim MK
• Lee KH
• Hyun MS

• KMID: 2252216
• DOI: http://doi.org/10.5045/kjh.2007.42.4.317

Abstract

BACKGROUND: The results of hematopoietic stem cell transplantation (HSCT) have been variable according to the patient disease status and center of treatment. We evaluated the outcome of HSCT in our pediatric and adolescent patients at Yeungnam University Hospital (YNUH).
METHODS
The records of 60 patients, ages 19 years and younger, who had a HSCT at YNUH from September 1995 to December 2006 were reviewed.
RESULTS
Among the 60 patients, allogeneic bone marrow transplantation (Allo-BMT) was performed in 19 (related 17, unrelated 2), cord blood transplantation (CBT) in 11 (related 1, unrelated 10), and autologous peripheral blood stem cell transplantation (Auto-PBSCT) in 30 patients. All patients engrafted. The median number of days to obtain an absolute neutrophil count >500/microL and platelet count >20,000/microL were 13 days (range, 8~48 days) and 27 days (range, 6~465 days), respectively. The treatment related mortality (TRM) of Allo-BMT, CBT and Auto-PBSCT were 21.1%, 27.3% and 10%. The three-year overall survival (OS) and event free survival (EFS) among the 60 patients were 73.3% and 63.3%. The three-year OS and EFS for Allo-BMT, CBT and Auto-PBSCT were 78.9% and 73.7%, 63.6% and 54.5% and 53.3% and 46.7%, respectively.
CONCLUSION
Although the number of cases was small, the 3-year EFS of the CBT was comparable to that of the Auto-PBSCT for hematological malignancies. However, the high TRM with the CBT requires further improvement as does the high relapse rates for the Auto-PBSCT, especially in neuroblastoma patients.

Keyword

Hematopoietic stem cell transplantation; Outcome; Children

MeSH Terms

Adolescent*
Bone Marrow Transplantation
Child
Disease-Free Survival
Fetal Blood
Hematologic Neoplasms
Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells*
Humans
Mortality
Neuroblastoma
Neutrophils
Peripheral Blood Stem Cell Transplantation
Platelet Count
Recurrence

Figure

• 

  Fig. 1 Overall survival and event free survival in total 60 patients.

• 

  Fig. 2 Overall survival and event free survival in Allo-BMT.

• 

  Fig. 3 Overall survival and event free survival in CBT.

• 

  Fig. 4 Overall survival and event free survival in Auto-PBSCT.

Reference

1). Bach FH., Albertini RJ., Joo P., Anderson JL., Bortin MM. Bone-marrow transplantation in a patient with Wiskott-Aldrich syndrome. Lancet. 1968. 2:1364–6.

2). Gluckman E., Rocha V., Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus Clin Biol. 2001. 8:146–54.

3). Ko YW., Lee YH., Hahan JS, et al. Bone marrow transplantation in adult severe aplastic anemia -a case report-. Korean J Hematol. 1982. 17:191–5.

4). Jo B., Kim HK., Kim CC., Han H. Successful engraftment of HLA-mismatched unrelated transplantation using banked cord blood in Korea. Korean J Hemato Stem Cell Trans. 1998. 3:125–8.

5). Kim HK., Cho B., Chung NG, et al. Two hundred cases of allogeneic hematopoietic stem cell transplantation in children: single center study. Korean J Hemato Stem Cell Trans. 2002. 7:63–71.

6). Lee S., Min WS., Min CK, et al. Allogeneic versus autologous hematopoietic stem cell transplantation for adults with high-risk acute lymphoblastic leukemia in first remission: a single experience. Korean J Hemato Stem Cell Trans. 2000. 5:141–52.

7). Shin EY. Autologous peripheral blood hematopoietic stem cell transplantation for children with acute myelogenous leukemia in Korea. Korean J Pediatr Hematol-Oncol. 2001. 8:9–16.

8). Sung KW., Lee SH., Park SM, et al. Allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia: a single center experience. Korean J Hemato Stem Cell Trans. 2004. 9:19–28.

9). Thomas E., Storb R., Clift RA, et al. Bone marrow transplantation (first of two parts). N Engl J Med. 1975. 292:832–43.

10). Shulman HM., Sullivan KM., Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980. 69:204–17.

11). Bensinger WI., Clift R., Martin P, et al. Allogenic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with bone marrow transplantation. Blood. 1996. 88:2794–800.

12). Kurtzberg J., Laughlin M., Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996. 335:157–66.

13). Horowitz MM., Rowlings PA. An update from the international bone marrow transplant registry and the autologous blood and marrow transplant registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol. 1997. 4:395–400.

14). Rosti G., Ferrante P., Ledermann J, et al. High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol. 2002. 41:129–40.

15). ASBMT, IBMTR, ABMTR Tandem BMT meetins. Biol Blood Marrow Transplant. 2001. 7:61–118.

16). Cho B. Pediatric allogeneic hematopoietic stem cell transplantation in Korea: April 2000: The Korean Society of Pediatric Hematology-Oncology. Korean J Pediatr Hematol-Oncol. 2001. 8:1–8.

17). Gluckman E., Rocha V., Boyer-Chammard A, et al. Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood Marrow Transplantation Group. N Engl J Med. 1997. 337:373–81.

18). Rocha V., Cornish J., Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001. 97:2962–71.

19). Bradley MB., Cairo MS. Cord blood immunology and stem cell transplantation. Hum Immunol. 2005. 66:431–46.

20). Schonberger S., Niehues T., Meisel R, et al. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population. Klin Padiatr. 2004. 216:356–63.

21). van der Meer A., Allebes WA., Paardekooper J., Ruiter J., Joosten I. HLA-C mismatches induce strong cytotoxic T-cell reactivity in the presence of an additional DRB/DQB mismatch and affect NK cell-mediated alloreactivity. Transplantation. 2001. 72:923–9.

22). Kletzel M., Katzenstein HM., Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002. 20:2284–92.

23). Rizzoli V., Carlo-Stella C. Stem cell purging: an intriguing dilemma. Exp Hamatol. 1995. 23:296–302.